Tandberg1 My read of the announcement is that SK is saying something that got abbreviated in the press release in a way that you could interpret either the study or enrollment is expected to be done by the end of the year. Since the next phase (1b) of the clinical program is said to already be underway, the rate of enrollment will drive completion. I recall it was Big On Tarvy who posted he heard that a press release would come from PPHM when enrollment is complete, so we may not need to wait until the end of the year to know the answer to your question.
PPHM making an oral presentation at the conference is excellent, as I have presented at large conferences and know that poster sessions are lucky to get more than a few dozen walk through observers, even at a conference with 5000 in attendance. Typically, large conferences like that have multiple tracks presenting simultaneously, so presenting as part of the primary agenda track gets the most attention. There are keynote sessions where everyone might hear the speaker, but that is usually reserved for special guest speakers. Also, the oral presentation slides in conference proceedings reported out afterwards tend to get more review from participants than poster sessions. I don't know if the AASLD does post conference CDs of presentations, but most major conferences do.
My speculation is that PPHM will have Phase 1b data by the end of the year, but will likely want a conference at which it can be presented, just as is the case for the reporting of the single dose trial at the October 30 AASLD. IMO, the AASLD is a fine conference selection for the HCV single dose presentation. What are likely conference candidates for 1b result reporting?
PL1- I will follow up on your suggestion to contact a broker or SEC rep to answer my short interest/index question and report back to the board if I get an answer.
I don't think that today's announcement does much more than give reinforcement to what folks on this board doing their DD had already figured out. However, release of HCV results in October should elicit more investor interest. Nice to know that reporting of hcv trial results has been formally announced.
Best wishes and IMO.
KT
